This morning ResMed Inc. (CHESS) posted an operating cash flow of US$94 million on revenues of US$523.7 million for the quarter ending September 30 2017.
It will pay a quarterly dividend of US35 cents per share on adjusted earnings of US66 cents per share that came in roughly in line with analysts’ estimates.
San Diego-based ResMed reports its results in U.S. dollars as its primary listing is on the NYSE, while it offers ownership interests to Australian investors on the ASX that represent a 1/10th interest in the NYSE scrip. As the US scrip sells for US$78.60 the Australian scrip closed yesterday at A$10.15 on a USD/AUD FX-adjusted basis.
The company intends to recommence its share buyback later in the fiscal year to buy back at a minimum sufficient stock to neutralise the dilutory effect of its employee share payment scheme.
For the quarter revenue increased 11 per cent on a constant currency basis, while the key gross margins lifted to 58.4 per cent compared to 57.8 per cent in the prior year’s quarter. Adjusted net income came in at US$86.1 million, up 13 per cent on the prior year’s quarter.
On a trailing basis the group trades on 28x trailing adjusted earnings per share of US$2.82 with the U.S. scrip selling for US$78.61.
Analysts are forecasting another year of strong growth with the first quarter traditionally softer than the financial year end period. ResMed retains its bullet point revenue growth track record and profit is starting to track higher again after some margin headwinds in its core U.S. market.
For Australian investors then it remains a good long-term bet thanks to its position as a healthcare leader in a large global addressable market that has reasonable barriers to entry. The company also remains founder-led with a strong market position as it moves into the cloud-connected digital healthcare space.
If there's one thing for sure, 2020 has been the year we embraced sanitisation. Scott Phillips has discovered a little-known Australian healthcare company could be set to reap the rewards of the post-covid world.
Better yet, this fast-growing company is currently trading at a 30% discount from its highs. Scott believes in this stock so much, he's staked $209k of our own company money on it. Forget 'buy now pay later', this stock could be the next hot stock on the ASX.
Scott and his team have published a detailed report on this tiny ASX stock. Find out how you can access our TOP healthcare stock today!
As of 2.11.2020
Motley Fool contributor Tom Richardson owns shares of ResMed Inc. The Motley Fool Australia has no position in any of the stocks mentioned.
You can find Tom on Twitter @tommyr345
We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
- On a serendipitous day, Tom Richardson is leaving the building – December 17, 2019 11:55am
- Why Aerometrex shares have doubled their IPO price – December 16, 2019 4:32pm
- Why the National Veterinary Care share price is going nuts today – December 16, 2019 3:39pm